Teva Pharmaceutical Industries (TEVA) Scheduled to Post Earnings on Wednesday

Teva Pharmaceutical Industries (NYSE:TEVA) is scheduled to be posting its quarterly earnings results before the market opens on Wednesday, May 8th. Analysts expect Teva Pharmaceutical Industries to post earnings of $0.49 per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, January 31st. The company reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.25. The business had revenue of $4.46 billion during the quarter, compared to analyst estimates of $3.97 billion. Teva Pharmaceutical Industries had a positive return on equity of 34.90% and a negative net margin of 3.33%. On average, analysts expect Teva Pharmaceutical Industries to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Teva Pharmaceutical Industries Stock Down 0.5 %

Teva Pharmaceutical Industries stock opened at $14.03 on Wednesday. The firm has a market cap of $15.73 billion, a price-to-earnings ratio of -29.85, a PEG ratio of 1.65 and a beta of 1.05. The stock has a fifty day simple moving average of $13.55 and a two-hundred day simple moving average of $11.50. Teva Pharmaceutical Industries has a 12 month low of $7.09 and a 12 month high of $14.47. The company has a current ratio of 1.02, a quick ratio of 0.69 and a debt-to-equity ratio of 2.23.

Wall Street Analyst Weigh In

Several brokerages recently commented on TEVA. Jefferies Financial Group raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $10.00 to $14.00 in a report on Tuesday, January 23rd. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 price objective for the company in a report on Friday, March 8th. Piper Sandler raised Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $12.00 to $19.00 in a report on Monday, February 12th. Barclays lifted their price objective on Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Monday, February 5th. Finally, StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 1st. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and an average price target of $13.78.

Insider Activity

In other news, CAO Amir Weiss sold 31,766 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $12.37, for a total value of $392,945.42. Following the transaction, the chief accounting officer now directly owns 10,676 shares in the company, valued at $132,062.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CAO Amir Weiss sold 31,766 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $12.37, for a total value of $392,945.42. Following the transaction, the chief accounting officer now directly owns 10,676 shares in the company, valued at $132,062.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Richard D. Francis sold 74,530 shares of the business’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $13.15, for a total value of $980,069.50. Following the completion of the sale, the chief executive officer now owns 87,125 shares in the company, valued at $1,145,693.75. The disclosure for this sale can be found here. Insiders have sold 390,738 shares of company stock worth $5,132,766 over the last ninety days. Corporate insiders own 0.55% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.